Therapeutic Horizons in Targeting EZH2 With Dual and Non‐PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives

Documenti analoghi

• A decade of research effort in synthesis, biological activity assessments, and mechanistic investigations of sulfamethazine‐incorporating molecules
  di: Hamada S. Abulkhair, et al.
  Pubblicazione: (2025)
• c‐KIT Small Molecule Inhibitors as a Therapeutic Strategy for Melanoma: Clinical Insights, SAR, and Future Directions
  di: Shubham C. Rivonker, et al.
  Pubblicazione: (2025)
• Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS‐CoV‐2 Mpro for Next‐Generation PROTAC‐Based Therapeutics
  di: Enrico Mario Alessandro Fassi, et al.
  Pubblicazione: (2025)
• Erratum: Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS‐CoV‐2 Mpro for Next‐Generation PROTAC‐Based Therapeutics
  Pubblicazione: (2026)
• AI‐Based Prediction of PROTAC‐ and Molecular Glue‐Mediated Ternary Complexes: A Comparative Evaluation of AlphaFold 3 and Boltz‐2
  di: Lino Riepenhausen, et al.
  Pubblicazione: (2026)